论文部分内容阅读
目的探讨康莱特(KLT)联合同步化疗治疗局部晚期非小细胞肺癌(NSCLC)的临床效果。方法按照治疗方法的区别,将近年来本院收治的70例局部晚期NSCLC患者分为观察组35例与对照组35例,两组患者均给予顺铂+盖诺疗法同步放化疗,其中放疗常规分割。2Gy/f,总量60Gy/f。在此基础上观察组患者每天再静脉滴注200 ml KLT注射液,21 d为一个疗程,共计2个疗程。通过体重变化、LPS评分观察患者生存质量的改善情况。结果两组患者的完全缓解率与治疗有效率差异无统计学意义(P>0.05),但观察组患者的骨髓抑制发生率、消化道不良反应及放射性食管炎的发生率均明显低于对照组(P<0.05),体重评分与治疗前后的KPS评分也明显优于对照组(P<0.05)。结论 KLT联合同步放化疗法能够降低局部晚期NSCLC患者放射性食管炎及骨髓抑制(3级以上)的发生率,减轻放化疗导致的胃肠道反应,显著提高患者的生存质量,进一步提高放化疗的疗效。
Objective To investigate the clinical effect of KLT combined with concurrent chemotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Seventy patients with locally advanced NSCLC admitted to our hospital in recent years were divided into observation group (n = 35) and control group (n = 35). Both groups were treated with cisplatin plus gynostemol concurrent chemoradiation, radiotherapy and conventional segmentation . 2Gy / f, total 60Gy / f. On this basis, patients in the observation group were given intravenous infusion of 200 ml of KLT daily for 21 days, a total of 2 courses. Through the change of body weight, LPS score observed quality of life in patients with improvement. Results There was no significant difference between the two groups in complete remission rate and treatment efficiency (P> 0.05). However, the incidence of bone marrow suppression, gastrointestinal adverse reactions and radiation esophagitis in the observation group were significantly lower than those in the control group (P <0.05). The scores of body weight and KPS before and after treatment were also significantly better than those of the control group (P <0.05). Conclusions KLT combined with concurrent radiochemotherapy can reduce the incidence of esophagitis and myelosuppression (grade 3 or above) in patients with locally advanced NSCLC, reduce the gastrointestinal reaction induced by radiotherapy and chemotherapy, significantly improve the quality of life of patients and further improve the efficacy of radiotherapy and chemotherapy Efficacy.